Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Peak Bio, Inc.
Peak Bio, Inc. Awarded Patent with Broad Coverage for Thailanstatin-ADC platform technology (PH-1) a Payload with Novel Immunomodulatory Effects that Target RNA Splicing
January 04, 2024
From
Peak Bio, Inc.
Via
GlobeNewswire
Tickers
PKBO
Peak Bio, Inc. Announces Filing of Provisional Patent Applications for PH-1, a Novel and Specific Immunomodulatory ADC payload platform targeting RNA splicing
September 19, 2023
From
Peak Bio, Inc.
Via
GlobeNewswire
Tickers
PKBO
Peak Bio, Inc. Announces Up-listing to OTCQB Market
August 31, 2023
From
Peak Bio, Inc.
Via
GlobeNewswire
Tickers
PKBO
Peak Bio, Inc., Announces Appointment of Michael Friedman to Board of Directors
August 31, 2023
From
Peak Bio, Inc.
Via
GlobeNewswire
Tickers
PKBO
Peak Bio, Inc. Announces its Application to Uplist to the OTCQB Venture Market
August 29, 2023
From
Peak Bio, Inc.
Via
GlobeNewswire
Tickers
PKBO
Peak Bio, Inc. Announces Amendment and Continued Access to Equity Line of up to $100 Million USD via an Accelerated Common Stock Purchase Transaction with White Lion Capital
August 24, 2023
From
Peak Bio, Inc.
Via
GlobeNewswire
Tickers
PKBO
Peak Bio, Inc. Presents Preclinical Data Highlighting Potential of Differentiated Trop2 PH1 (Novel Payload) ADC in Poster at 2023 AACR Annual Meeting
August 23, 2023
From
Peak Bio, Inc.
Via
GlobeNewswire
Tickers
PKBO
Peak Bio, Inc. Announces Closing of up to $100 Million Common Stock Purchase Transaction with White Lion Capital
November 04, 2022
From
Peak Bio, Inc.
Via
Business Wire
Tickers
PKBO
Peak Bio Co., Ltd. to List on NASDAQ Following Successful Business Combination with Ignyte Acquisition Corp.
November 02, 2022
From
Peak Bio, Inc.
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.